Head to Head Survey: IceCure Medical (ICCM) versus Its Competitors

IceCure Medical (NASDAQ:ICCM) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare IceCure Medical to related businesses based on the strength of its earnings, profitability, institutional ownership, dividends, risk, valuation and analyst recommendations.

Volatility & Risk

IceCure Medical has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, IceCure Medical’s competitors have a beta of 2.57, indicating that their average stock price is 157% more volatile than the S&P 500.

Profitability

This table compares IceCure Medical and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
IceCure Medical Competitors	-278.23%	-150.06%	-21.87%

Institutional & Insider Ownership

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares IceCure Medical and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
IceCure Medical	$3.38 million	-$15.06 million	-0.10
IceCure Medical Competitors	$1.89 billion	$138.79 million	10.75

IceCure Medical’s competitors have higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for IceCure Medical and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1	1	2	0	2.25
IceCure Medical Competitors	4257	10481	18203	824	2.46

IceCure Medical presently has a consensus price target of $30.00, indicating a potential upside of 3,347.88%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.29%. Given IceCure Medical’s higher possible upside, equities research analysts clearly believe IceCure Medical is more favorable than its competitors.

Summary

IceCure Medical competitors beat IceCure Medical on 12 of the 13 factors compared.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.